Browse the corpus

REFERENCES Adès L, Sanz MA, Chevret S, et al, “Treatment of Newly Diagnosed Acute Promyelocytic Leukemia (APL): A Comparison of French-Belgian-Swiss and PETHEMA Results,” Blood , 2008, 111(3):1078-84. [PubMed 17975017 ] Bargetzi MJ, Tichelli A, Gratwohl A, et al, “Oral All-Transretinoic Acid Administration in Intubated Patients With Acute Promyelocytic Leukemia,” Schweiz Med Wochenschr , 1996, 126(45):1944-5. [PubMed 8946598 ] Chen GQ, Shen ZX, Wu F, et al, “Pharmacokinetics and Efficacy of Low-Dose All- trans Retinoic Acid in the Treatment of Acute Promyelocytic Leukemia,” Leukemia , 1996, 10(5):825-8. [PubMed 8656678 ] Estey E, Garcia-Manero G, Ferrajoli A, et al, "Use of All- Trans Retinoic Acid Plus Arsenic Trioxide as an Alternative to Chemotherapy in Untreated Acute Promyelocytic Leukemia," Blood , 2006, 107(9):3469-73. [PubMed 16373661 ] Gregory J, Kim H, Alonzo T, et al, “Treatment of Children With Acute Promyelocytic Leukemia: Results of the First North American Intergroup Trial INT0129,” Pediatr Blood Cancer , 2009, 53(6):1005-10. [PubMed 19743516 ] Kueh YK, Liew PP, Ho PC, et al, “Sublingual Administration of All- Trans -Retinoic Acid to a Comatose Patient With Acute Promyelocytic Leukemia,” Ann Pharmacother , 1999, 33(4):503-5. [PubMed 10332546 ] Kurzrock R, Estey E, and Talpaz M, “All- trans Retinoic Acid: Tolerance and Biologic Effects in Myelodysplastic Syndrome,” J Clin Oncol , 1993, 11(8):1489-95. [PubMed 8336187 ] Lazzarino M, Regazzi MB, and Corso A, “Clinical Relevance of All- trans Retinoic Acid Pharmacokinetics and Its Modulation in Acute Promyelocytic Leukemia,” Leuk Lymphoma , 1996, 23(5-6):539-43. [PubMed 9031084 ] Lo Coco F, Avvisati G, Vignetti M, et al, “Front-Line Treatment of Acute Promyelocytic Leukemia With AIDA Induction Followed by Risk-Adapted Consolidation for Adults Younger Than 61 Years: Results of the AIDA-2000 Trial of the GIMEMA Group,” Blood , 2010, 116(17):3171-9. [PubMed 20644121 ] Montesinos P, Bergua JM, Vellenga E, et al, “Differentiation Syndrome in Patients With Acute Promyelocytic Leukemia Treated with All- Trans Retinoic Acid and Anthracycline Chemotherapy: Characteristics, Outcomes, and Prognostic Factors,” Blood , 2009, 113(4):775-83. [PubMed 18945964 ]

Lo Coco F, Avvisati G, Vignetti M, et al, “Front-Line Treatment of Acute Promyelocytic Leukemia With AIDA Induction Followed by Risk-Adapted Consolidation for Adults Younger Than 61 Years: Results of the AIDA-2000 Trial of the GIMEMA Group,” Blood , 2010, 116(17):3171-9. [PubMed 20644121 ] Montesinos P, Bergua JM, Vellenga E, et al, “Differentiation Syndrome in Patients With Acute Promyelocytic Leukemia Treated with All- Trans Retinoic Acid and Anthracycline Chemotherapy: Characteristics, Outcomes, and Prognostic Factors,” Blood , 2009, 113(4):775-83. [PubMed 18945964 ] Muindi JR, Frankel SR, Huselton C, et al, “Clinical Pharmacology of Oral All- trans Retinoic Acid in Patients With Acute Promyelocytic Leukemia,” Cancer Res , 1992, 52(8):2138-42. [PubMed 1559217 ] National Institute for Occupational Safety and Health (NIOSH), "NIOSH List of Antineoplastic and Other Hazardous Drugs in Healthcare Settings 2012." Available at file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf . Accessed January 21, 2013. Ortega JJ, Madero L, Martin G, et al, “Treatment With All- Trans Retinoic Acid and Anthracycline Monochemotherapy for Children With Acute Promyelocytic Leukemia: A Multicenter Study by the PETHEMA Group,” J Clin Oncol , 2005, 23(30):7632-40. [PubMed 16234524 ] Powell BL, Moser B, Stock W, et al, “Arsenic Trioxide Improves Event-Free and Over-All Survival for Adults With Acute Promyelocytic Leukemia: North American Leukemia Intergroup Study C9710,” Blood , 2010, 116(19):3751-7. [PubMed 20705755 ] Ravandi F, Estey E, Jones D, et al, "Effective Treatment of Acute Promyelocytic Leukemia With All- Trans -Retinoic Acid, Arsenic Trioxide, and Gemtuzumab Ozogamicin," J Clin Oncol , 2009, 27(4):504-10. [PubMed 19075265 ] Sanz MA, Grimwade D, Tallman MS, et al, “Management of Acute Promyelocytic Leukemia: Recommendations From an Expert Panel on Behalf of the European LeukemiaNet,” Blood , 2009, 113(9):1875-91. [PubMed 18812465 ] Sanz MA, Martin G, Gonzalez M, et al, “Risk-Adapted Treatment of Acute Promyelocytic Leukemia With All- Trans -Retinoic Acid and Anthracycline Monochemotherapy: A Multicenter Study by the PETHEMA Group,” Blood , 2004, 103(4):1237-43. [PubMed 14576047 ]

Sanz MA, Grimwade D, Tallman MS, et al, “Management of Acute Promyelocytic Leukemia: Recommendations From an Expert Panel on Behalf of the European LeukemiaNet,” Blood , 2009, 113(9):1875-91. [PubMed 18812465 ] Sanz MA, Martin G, Gonzalez M, et al, “Risk-Adapted Treatment of Acute Promyelocytic Leukemia With All- Trans -Retinoic Acid and Anthracycline Monochemotherapy: A Multicenter Study by the PETHEMA Group,” Blood , 2004, 103(4):1237-43. [PubMed 14576047 ] Sanz MA, Montesinos P, Rayón C, et al, “Risk-Adapted Treatment of Acute Promyelocytic Leukemia Based on all-trans Retinoic Acid and Anthracycline With Addition of Cytarabine in Consolidation Therapy for High-Risk Patients: Further Improvements in Treatment Outcome,” Blood , 2010, 115(25):5137-46. [PubMed 20393132 ] Sanz MA, Montesinos P, Vellenga E, et al, “Risk-Adapted Treatment of Acute Promyelocytic Leukemia With All- Trans -Retinoic Acid and Anthracycline Monochemotherapy: Long-Term Outcome of the LPA 99 Multicenter Study by the PETHEMA Group,” Blood , 2008, 112(8):3130-4. [PubMed 18664623 ] Shaw PJ, Atkins MC, Nath CE, et al, ”ATRA Administration in the Critically Ill Patient,” Leukemia , 1995, 9(7):1288. [PubMed 7630206 ] Smith MA, Adamson PC, Balis FM, et al, “Phase I and Pharmacokinetic Evaluation of All- trans -Retinoic Acid in Pediatric Patients With Cancer,” J Clin Oncol , 1992, 10(11):1666-73. [PubMed 1403049 ] Takitani K, Nakao Y, Kosada Y, et al, “Low Plasma Levels of All- Trans Retinoic Acid After Feeding Tube Administration for Acute Promyelocytic Leukemia,” Am J Hematol , 2004, 76(1):97-8. [PubMed 15114613 ] Testi AM, Biondi A, Lo Coco F, et al, “GIMEMA_AIEOPAIDA Protocol for the Treatment of Newly Diagnosed Acute Promyelocutic Leukemia (APL) in Children,” Blood , 2005, 106(2): 447-53. [PubMed 15677559 ] Topic 9262 Version 38.0 © 2013 UpToDate, Inc. All rights reserved. | Subscription and License Agreement | Release: 21.6- C21.56 Licensed to: AsanBook Dig. Med. Lib. | Support Tag: [1004-58.240.98.179-2345798AF2-S244013.14]